Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin

FEBS Journal

Volumn 279, Issue 14, 2012, Pages 2555-2567

  Edupuganti, Om P ^a   Ovsepian, Saak V ^a   Wang, Jiafu ^a   Zurawski, Tomas H ^a   Schmidt, James J ^b   Smith, Leonard ^b   Lawrence, Gary W ^a   Dolly, J Oliver ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

biotin streptavidin conjugation; neuromuscular transmission; pharmaceutical carriers; SNAP 25

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN F; DRUG CARRIER; LIPOSOME; PROTEINASE INHIBITOR; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG DELIVERY SYSTEM; DRUG TARGETING; HEMIDIAPHRAGM; LIGHT CHAIN; MOUSE; NERVE ENDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PARALYSIS; PRESYNAPTIC NERVE; PRIORITY JOURNAL;

ANIMALS; BOTULINUM TOXINS; DIAPHRAGM; DRUG DELIVERY SYSTEMS; FLUORESCEIN; HUMANS; LIPOSOMES; MICE; MICROSCOPY, CONFOCAL; MOTOR NEURONS; MUTATION; NERVE ENDINGS; PARALYSIS; PRESYNAPTIC TERMINALS; PROTEASE INHIBITORS; RECOMBINANT FUSION PROTEINS; SNARE PROTEINS; STREPTAVIDIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

ESCHERICHIA COLI;

EID: 84863497196     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08638.x     Document Type: Article

References (48)

1. Costantino L, Tosi G, Ruozi B, Bondioli L, Vandelli MA, &, Forni F, (2009) Chapter 3-Colloidal systems for CNS drug delivery. Prog Brain Res 180, 35-69.
2. Tarahovsky YS, (2011) "Smart" liposomal nanocontainers in biology and medicine. Biochemistry (Mosc) 75, 811-824.
3. Torchilin VP, (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4, 145-160. (Pubitemid 40282557)
4. Venkatraman SS, Ma LL, Natarajan JV, &, Chattopadhyay S, (2010) Polymer- and liposome-based nanoparticles in targeted drug delivery. Front Biosci (Schol Ed) 2, 801-814.
5. Conwell CC, &, Huang L, (2005) Recent advances in non-viral gene delivery. Adv Genet 53, 3-18.
6. Gregoriadis G, &, Florence AT, (1993) Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 45, 15-28. (Pubitemid 23093890)
7. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, &, Blumenthal R, (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26, 523-580.
8. Schlachetzki F, Zhang Y, Boado RJ, &, Pardridge WM, (2004) Gene therapy of the brain: the trans-vascular approach. Neurology 62, 1275-1281. (Pubitemid 38526037)
9. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, &, George JM, (2009) Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 284, 6972-6981.
10. Andreu A, Fairweather N, &, Miller AD, (2008) Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS. ChemBioChem 9, 219-231. (Pubitemid 351196790)
11. Dolly JO, Lawrence GW, Meng J, Wang J, &, Ovsepian SV, (2009) Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol 9, 326-335.
12. Zhang P, Ray R, Singh BR, Li D, Adler M, &, Ray P, (2009) An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 9, 12.
13. Singh BR, Thirunavukkarasu N, Ghosal K, Ravichandran E, Kukreja R, Cai S, Zhang P, Ray R, &, Ray P, (2010) Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 92, 1252-1259.
14. de Paiva A, Poulain B, Lawrence GW, Shone CC, Tauc L, &, Dolly JO, (1993) A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J Biol Chem 268, 20838-20844. (Pubitemid 23292258)
15. Daniels-Holgate PU, &, Dolly JO, (1996) Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain. J Neurosci Res 44, 263-271. (Pubitemid 26134416)
16. Lalli G, Herreros J, Osborne SL, Montecucco C, Rossetto O, &, Schiavo G, (1999) Functional characterisation of tetanus and botulinum neurotoxins binding domains. J Cell Sci 112 (Pt 16), 2715-2724. (Pubitemid 29429794)
17. O'Leary VB, Ovsepian SV, Raghunath A, Huo Q, Lawrence GW, Smith L, &, Dolly JO, (2011) Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons. Gene Ther 18, 656-665.
18. Black JD, &, Dolly JO, (1986) Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 103, 521-534. (Pubitemid 16055048)
19. de Paiva A, &, Dolly JO, (1990) Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes. FEBS Lett 277, 171-174.
20. Schmidt JJ, &, Stafford RG, (2002) A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett 532, 423-426. (Pubitemid 35441386)
21. Schmidt JJ, &, Stafford RG, (2005) Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry 44, 4067-4073. (Pubitemid 40358059)
22. Jones MA, Singh A, Kilpatrick PK, &, Carbonell RG, (1993) Preparation and characterization of ligand-modified labelled liposomes for solid phase immunoassays. J Liposome Res 3, 793-804. (Pubitemid 24007439)
23. Eberhorn AC, Horn AK, Eberhorn N, Fischer P, Boergen KP, &, Buttner-Ennever JA, (2005) Palisade endings in extraocular eye muscles revealed by SNAP-25 immunoreactivity. J Anat 206, 307-315. (Pubitemid 40424850)
24. Maisey EA, Wadsworth JD, Poulain B, Shone CC, Melling J, Gibbs P, Tauc L, &, Dolly JO, (1988) Involvement of the constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release. Eur J Biochem 177, 683-691.
25. Poulain B, Tauc L, Maisey EA, Wadsworth JD, Mohan PM, &, Dolly JO, (1988) Neurotransmitter release is blocked intracellularly by botulinum neurotoxin, and this requires uptake of both toxin polypeptides by a process mediated by the larger chain. Proc Natl Acad Sci USA 85, 4090-4094.
26. Nakai N, Lai CY, &, Horecker BL, (1974) Use of fluorescamine in the chromatographic analysis of peptides from proteins. Anal Biochem 58, 563-570.
27. Goodnough MC, Oyler G, Fishman PS, Johnson EA, Neale EA, Keller JE, Tepp WH, Clark M, Hartz S, &, Adler M, (2002) Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett 513, 163-168. (Pubitemid 34251257)
28. Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM, Finn DP, Wheeler L, &, Dolly JO, (2011) A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 286, 6375-6385.
29. Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G, Bigalke H, &, Binz T, (2004) Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem 91, 1461-1472. (Pubitemid 39658572)
30. Fischer A, &, Montal M, (2007) Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci USA 104, 10447-10452. (Pubitemid 47185685)
31. Pellett S, Tepp WH, Stanker LH, Band PA, Johnson EA, &, Ichtchenko K, (2011) Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. Biochem Biophys Res Commun 405, 673-677.
32. Farrugia ME, &, Vincent A, (2010) Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 23, 489-495.
33. Murray LM, Talbot K, &, Gillingwater TH, (2010) Review: neuromuscular synaptic vulnerability in motor neurone disease: amyotrophic lateral sclerosis and spinal muscular atrophy. Neuropathol Appl Neurobiol 36, 133-156.
34. Senanayake N, &, Roman GC, (1992) Disorders of neuromuscular transmission due to natural environmental toxins. J Neurol Sci 107, 1-13.
35. Dong M, Richards DA, Goodnough MC, Tepp WH, Johnson EA, &, Chapman ER, (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162, 1293-1303. (Pubitemid 37210885)
36. Nishiki T, Tokuyama Y, Kamata Y, Nemoto Y, Yoshida A, Sato K, Sekiguchi M, Takahashi M, &, Kozaki S, (1996) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett 378, 253-257.
37. Cherington M, (2004) Botulism: update and review. Semin Neurol 24, 155-163. (Pubitemid 38971842)
38. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285, 1059-1070. (Pubitemid 32176420)
39. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, Oyler GA, &, Weissman AM, (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA 107, 16554-16559.
40. Sudhof TC, &, Rizo J, (1996) Synaptotagmins: C2-domain proteins that regulate membrane traffic. Neuron 17, 379-388. (Pubitemid 26322210)
41. Maejima T, Hashimoto K, Yoshida T, Aiba A, &, Kano M, (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31, 463-475. (Pubitemid 32778564)
42. Van Broeck B, Chen JM, Treton G, Desmidt M, Hopf C, Ramsden N, Karran E, Mercken M, &, Rowley A, (2011) Chronic treatment with a novel gamma-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. Br J Pharmacol 163, 375-389.
43. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, &, Chapman ER, (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596.
44. Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR, Lawrence GW, &, Dolly JO, (2009) Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 29, 4981-4992.
45. Dolly JO, Wang J, Zurawski TH, &, Meng J, (2011) Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J 278, 4454-4466.
46. Wang J, Meng J, Lawrence GW, Zurawski TH, Sasse A, Bodeker MO, Gilmore MA, Fernandez-Salas E, Francis J, Steward LE, et al. (2008) Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem 283, 16993-17002.
47. Medina LA, Calixto SM, Klipper R, Li Y, Phillips WT, &, Goins B, (2006) Mediastinal node and diaphragmatic targeting after intracavitary injection of avidin/99mTc-blue-biotin-liposome system. J Pharm Sci 95, 207-224.
48. Lawrence G, Wang J, Chion CK, Aoki KR, &, Dolly JO, (2007) Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E. J Pharmacol Exp Ther 320, 410-418. (Pubitemid 46025755)